Evi Struble

Dr. Evi Struble

Laboratory of Plasma Derivatives, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
PZPei Zhang
Pei Zhang
LZLilin Zhong
Lilin Zhong
ESEvi Struble
Evi Struble
HWHisayoshi Watanabe
Hisayoshi Watanabe
AKAlla Kachko
Alla Kachko
MMMarian Major
Marian Major
Using human immune globulins made from antihepatitis C virus (HCV)-positive plasma, we recently identified two antibody epitopes in the E2 protein at residues 412–426 (epitope I) and 434–446 (epitope II). Whereas epitope I is highly conserved among genotypes, epitope II varies. We discovered that epitope I was implicated in HCV neutralization whereas the binding of non-neutralizing antibody to epitope II disrupted virus neutralization mediated by antibody binding at epitope I. These findings suggested that, if this interfering mechanism operates in vivo during HCV infection, a neutralizing antibody against epitope I can be restrained by an interfering antibody, which may account for the persistence of HCV even in the presence of an abundance of neutralizing antibodies. We tested this hypothesis by affinity depletion and peptide-blocking of epitope-II-specific antibodies in plasma of a chronically HCV-infected patient and recombinant E1E2 vaccinated chimpanzees. We demonstrate that, by removing the restraints imposed by the interfering antibodies to epitope-II, neutralizing activity can be revealed in plasma that previously failed to neutralize viral stock in cell culture. Further, cross-genotype neutralization could be generated from monospecific plasma. Our studies contribute to understanding the mechanisms of antibody-mediated neutralization and interference and provide a practical approach to the development of more potent and broadly reactive hepatitis C immune globulins.

15 April 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
LDLu Deng
Lu Deng
LZLilin Zhong
Lilin Zhong
ESEvi Struble
Evi Struble
HDHongying Duan
Hongying Duan
LMLi Ma
Li Ma
PZPei Zhang
Pei Zhang
Hepatitis C virus (HCV) envelope glycoprotein E2 has been considered as a major target for vaccine design. Epitope II, mapped between residues 427–446 within the E2 protein, elicits antibodies that are either neutralizing or nonneutralizing. The fundamental mechanism of antibody-mediated neutralization at epitope II remains to be defined at the atomic level. Here we report the crystal structure of the epitope II peptide in complex with a monoclonal antibody (mAb#8) capable of neutralizing HCV. The complex structure revealed that this neutralizing antibody engages epitope II via interactions with both the C-terminal α-helix and the N-terminal loop using a bifurcated mode of action. Our structural insights into the key determinants for the antibody-mediated neutralization may contribute to the immune prophylaxis of HCV infection and the development of an effective HCV vaccine.

7 July 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
LDLu Deng
Lu Deng
LMLi Ma
Li Ma
MVMaria Luisa Virata
Maria Luisa Virata
LZLilin Zhong
Lilin Zhong
HYHailing Yan
Hailing Yan
PZPei Zhang
Pei Zhang
Significance: X-ray crystallographic analysis revealed that one of the critical antibody-binding sites on the hepatitis C virus exists in different shapes. The structural transition among these shapes is governed by a highly conserved glycine residue that serves as a flexible joint connecting the two essential parts of the binding site; that is, the C-terminal α-helix and the N-terminal loop. It is the particular spatial arrangement of these parts that determines the specificity of antibody recognition and, consequently, the outcome of either neutralization or nonneutralization of the virus. These structural insights may be beneficial for the immune prophylaxis and treatment of HCV infections.

1 January 2012 in Biochimica et Biophysica Acta (BBA) - General Subjects
Verified
Journal Article
Closed access
MRMohsen Rajabi
Mohsen Rajabi
ESEvi Struble
Evi Struble
ZZZhaohua Zhou
Zhaohua Zhou
EKElena Karnaukhova
Elena Karnaukhova

1 December 2012 in Journal of Virology
Verified
Journal Article
Open access
PDF file
HDHongying Duan
Hongying Duan
AKAlla Kachko
Alla Kachko
LZLilin Zhong
Lilin Zhong
ESEvi Struble
Evi Struble
SPShivani Pandey
Shivani Pandey
PZPei Zhang
Pei Zhang
Antibodies to epitopes in the E2 protein of hepatitis C virus (HCV) reduce the viral infectivity in vivo and in vitro . However, the virus can persist in patients in the presence of neutralizing antibodies. In this study, we generated a panel of monoclonal antibodies that bound specifically to the region between residues 427 and 446 of the E2 protein of HCV genotype 1a, and we examined their capacity to neutralize HCV in a cell culture system. Of the four monoclonal antibodies described here, two were able to neutralize the virus in a genotype 1a-specific manner. The other two failed to neutralize the virus. Moreover, one of the nonneutralizing antibodies could interfere with the neutralizing activity of a chimpanzee polyclonal antibody at E2 residues 412 to 426, as it did with an HCV-specific immune globulin preparation, which was derived from the pooled plasma of chronic hepatitis C patients. Mapping the epitope-paratope contact interfaces revealed that these functionally distinct antibodies shared binding specificity for key amino acid residues, including W 437 , L 438 , L 441 , and F 442 , within the same epitope of the E2 protein. These data suggest that the effectiveness of antibody-mediated neutralization of HCV could be deduced from the interplay between an antibody and a specific set of amino acid residues. Further understanding of the molecular mechanisms of antibody-mediated neutralization and nonneutralization should provide insights for designing a vaccine to control HCV infection in vivo .

19 May 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ESEvi Struble
Evi Struble
JRJonathan Rawson
Jonathan Rawson
TSTzanko Stantchev
Tzanko Stantchev
DSDorothy Scott
Dorothy Scott
MSMarjorie Shapiro
Marjorie Shapiro
Viral diseases represent a major public health concerns and ever-present risks for developing into future pandemics. Antiviral antibody therapeutics, either alone or in combination with other therapies, emerged as valuable preventative and treatment options, including during global emergencies. Here we will discuss polyclonal and monoclonal antiviral antibody therapies, focusing on the unique biochemical and physiological properties that make them well-suited as therapeutic agents. We will describe the methods of antibody characterization and potency assessment throughout development, highlighting similarities and differences between polyclonal and monoclonal products as appropriate. In addition, we will consider the benefits and challenges of antiviral antibodies when used in combination with other antibodies or other types of antiviral therapeutics. Lastly, we will discuss novel approaches to the characterization and development of antiviral antibodies and identify areas that would benefit from additional research.